The 2026 Magtein clinical trial by Lopresti and Smith, published in Frontiers in Nutrition, was a six-week randomized, double-blind, placebo-controlled study. Specifically, it examined Magtein® (magnesium L-threonate) for cognitive performance, self-reported sleep outcomes, and sleep-time body measures in 100 healthy adults aged 18 to 45.
Direct answer
The trial reported greater improvements with Magtein® than placebo in overall cognitive performance and sleep-related impairment. In addition, it found significant between-group differences in sleep heart rate and HRV, adding a new body-measure dimension to the growing Magtein® clinical evidence base.
Trial at a glance
Figure 1 summarizes the design of the six-week randomized, double-blind, placebo-controlled trial. Specifically, it shows the study population, treatment groups, intervention period, and main assessments [1].
How the 2026 Magtein clinical trial reflects changing brain-health research
Today, more adults report poor sleep, mental fatigue, and stress that does not fully clear by morning. As this picture has become more complex, researchers have developed broader ways to study and support brain health.
Why multidimensional measurement matters
As a result, modern trials no longer ask only whether a nutrient changes a single questionnaire score. They now ask sharper questions:
How do you measure cognition meaningfully in healthy adults who already perform well?
How do you assess sleep when subjective experience and physiology don’t always align?
And how do you bring autonomic recovery — heart rate, HRV, autonomic balance — into a cognitive-health study?
Why this matters: Most adults aren’t experiencing severe cognitive decline. They’re experiencing subtle dips in focus, recovery, and mental sharpness that don’t register on traditional clinical measures but show up clearly in everyday life. Accordingly, the science has had to evolve to match that reality.
Against this background, the 2026 Magtein clinical trial, published in Frontiers in Nutrition, set out to address all three within a single study design [1].
Over six weeks, this randomized, double-blind, placebo-controlled trial examined Magtein® (magnesium L-threonate) in 100 healthy adults aged 18–45 years with self-reported dissatisfied sleep [1]. In addition, participants completed tested assessments covering cognition, sleep quality, wellbeing, and sleep-time autonomic measures.
More broadly, the trial reflects the continued growth of the Magtein® (magnesium L-threonate) clinical research program.
Why has magnesium been difficult to study in brain health?
To understand the challenge, magnesium has historically been difficult to study in brain health because most magnesium forms have limited published evidence showing a meaningful rise in brain magnesium after oral intake. Elevating magnesium in the blood does not necessarily translate to elevated magnesium concentrations within the brain.
At a biological level, magnesium itself plays a fundamental role in human biology. It serves as a cofactor in more than 300 enzymatic reactions, modulates NMDA receptor activity, and supports the synaptic plasticity involved in learning and memory.
At the same time, inadequate magnesium intake remains common. National Health and Nutrition Examination Survey (NHANES) analyses indicate many US adults fall short of recommended intake [2], and global modeling suggests widespread dietary magnesium inadequacy worldwide [3]. (For background on how magnesium forms differ, see The Different Forms of Magnesium and Why Magtein® Stands Apart.)
Why brain magnesium distribution matters
Despite this biological basis, translating magnesium science into measurable cognitive outcomes has historically been challenging — in large part because of distribution. Most magnesium forms have limited published evidence supporting meaningful brain magnesium elevation after oral administration [4], [5].
For this reason, magnesium L-threonate (Magtein®) was developed specifically to address this challenge — a brain-delivery mechanism we explore in more depth in How Magtein® Crosses the Blood-Brain Barrier (and Why It Matters). Preclinical studies have reported that magnesium L-threonate raises brain magnesium concentrations and supports synaptic density and plasticity-related pathways [4], [5]. Importantly, this brain-delivery mechanism has not yet been established in published literature for other commonly used magnesium forms.
Key takeaway: Raising magnesium in the blood is not the same as raising magnesium in the brain. That distinction is part of what makes magnesium L-threonate a scientifically distinct compound to study.
Together, this scientific foundation helps explain why Magtein® has become one of the more clinically studied magnesium forms in cognitive and sleep-health research.
Building on this foundation, the 2026 Magtein clinical trial draws on earlier human studies in older adults [6], healthy Chinese adults [7], and middle-aged adults [8].
What was the design of the 2026 Magtein clinical trial?
Lopresti and Smith conducted the 2026 Magtein clinical trial as a six-week, two-arm, parallel-group, randomized, double-blind, placebo-controlled study of Magtein® (2 g/day) versus matched placebo in 100 healthy adults aged 18 to 45.
Clinical Research Australia conducted the study in Perth, Western Australia. Before recruitment, the researchers registered it with the Australian and New Zealand Clinical Trials Registry (ANZCTR), and the National Institute of Integrative Medicine Human Research Ethics Committee approved the protocol. Recruitment then occurred between April and November 2024.
Next, the investigators randomly assigned participants to receive either:
2 g/day of Magtein® (magnesium L-threonate)
or matched placebo capsules
Participants in the Magtein® group received 1 g in the morning and 1 g about two hours before bedtime, providing about 145 mg of elemental magnesium daily.
How were baseline and follow-up visits structured?
At baseline, participants completed an in-person visit followed by seven days of Oura Ring monitoring. They also completed online questionnaires during the intervention and a final in-person assessment at week six. In addition, the trial standardized caffeine, alcohol, exercise, and breakfast timing before visits to reduce variability.
How did the investigators maintain blinding integrity?
At study completion, the researchers formally checked whether blinding had worked. Most participants either guessed incorrectly or remained unsure of their group assignment.
Moreover, compliance was high: 96 of 100 participants completed the trial, and 92% of those participants took more than 80% of their capsules.
These details matter because rigorous execution gives a small trial meaningful signal value.
Why did the population selection matter?
This population selection mattered because cognition and sleep trials often produce ceiling effects in fully healthy participants, leaving little room to detect improvement. Similarly, sleep trials face the same problem when participants already have objectively healthy sleep architecture.
How the investigators reduced ceiling effects
To address this challenge, the investigators recruited healthy adults who had experienced self-reported dissatisfied sleep for longer than four weeks. Participants did not have diagnosed neurological, psychiatric, or sleep disorders.
As a result, the cohort had real-world room to improve without including a clinically impaired population.
In practical terms, the study examined people who functioned normally day to day but experienced subtle issues such as poor sleep quality, reduced mental sharpness, daytime fatigue, or slower cognitive recovery. This cohort more closely reflects the people who often reach for magnesium in everyday life.
In plain terms: The study focused on generally healthy adults who nevertheless reported ongoing sleep dissatisfaction. Exploratory subgroup findings suggested stronger sleep-related signals among participants with greater baseline difficulties, but those analyses require confirmation.
What assessments did the study use?
To capture the full picture, the researchers combined tested cognitive tasks, self-reported sleep measures, wearable monitoring, and measures of autonomic function.
Cognitive assessments. First, the researchers selected the NIH Toolbox Total Cognition Composite [9], a tested computer-based set of tasks covering working memory, attention, processing speed, episodic memory, language, and inhibitory control. The trial also included Raven’s Progressive Matrices [10], a non-verbal test of fluid reasoning.
Sleep and wellbeing. Second, the researchers measured subjective sleep outcomes using the PROMIS Sleep Disturbance and Sleep-Related Impairment scales [11], the Restorative Sleep Questionnaire [12], and the WHO-5 Wellbeing Index [13].
Objective monitoring. Third, the researchers used the Oura Ring to monitor sleep architecture, sleep heart rate, and heart rate variability (RMSSD) [14].
Additional features. In addition, the study included a visuo-motor Aim Trainer task, expectancy-bias controls, and a cognitive-age translation model.
Together, these tools provided a broader picture than many standard supplement studies.
What did the 2026 Magtein clinical trial report on cognition?
At week six, participants receiving Magtein® showed a significantly greater improvement in the NIH Total Cognition Composite compared with placebo (p = 0.043). Meanwhile, the Magtein® group improved by 8.40 points compared with 5.60 points in the placebo group.
As shown in Figure 2, mean NIH Toolbox Total Cognition Composite scores increased from 112.06 at baseline to 120.46 at week six in the Magtein® group, compared with an increase from 110.82 to 116.42 in the placebo group. The time-by-group interaction was statistically significant (p = 0.043) [1].
Where did the strongest cognitive effects appear?
More specifically, the clearest signals appeared in working-memory and episodic-memory measures.
For example, the List Sorting Working Memory task reached statistical significance (p = 0.033), and the Picture Sequence Memory task showed a positive trend.
In contrast, Raven’s 2 fluid-reasoning scores did not differ between groups.
How the magnesium L-threonate clinical trial aligns with mechanism
From a biological perspective, that selective pattern is consistent with the biology. Working memory and episodic memory rely heavily on prefrontal and hippocampal circuitry — the same systems linked to the synaptic effects observed in Magtein® preclinical research [4], [5]. The synaptic-plasticity story is explored at greater length in The Neuroplasticity Link: How Magnesium L-Threonate Supports Synaptic Flexibility.
Key takeaway: The significant individual-task result was in working memory, while episodic memory showed a non-significant positive trend and fluid reasoning did not differ between groups. This pattern is biologically interesting, but it remains hypothesis-supporting rather than proof of a mechanism in humans.
What did the cognitive-age analysis show?
Notably, one of the most discussed findings from the study was the “cognitive age” translation.
Specifically, the trial reported a 2.24-point between-group difference on the NIH Change Sensitive Score at week six. Using NIH normative references, this translated to about 7.5 years on the normative cognitive-aging curve [15]. However, this is a derived statistical interpretation, not a direct measurement of biological cognitive age. It’s best read as an intuitive way of contextualizing what the cognitive differences mean in everyday terms — a concept we discuss further in Magtein® and a Healthier Brain Age.
What new measurement approach did the study introduce?
In addition, the study reported a significantly greater change versus placebo in a digital visuo-motor Aim Trainer task (p = 0.031). According to the authors, this was among the first uses of this type of digital performance assessment in a magnesium clinical trial, making it an exploratory direction for future research.
What did the Magtein cognition and sleep study report on sleep?
For sleep, the Magtein® group reported significantly greater improvement in PROMIS Sleep-Related Impairment versus placebo (p = 0.043). An exploratory subgroup with greater baseline sleep-related impairment showed a larger difference, which should be confirmed in a prospectively designed study.
However, the sleep findings revealed an important difference between subjective and objective results. Objective sleep architecture did not differ significantly between groups, and some subjective scales remained non-significant in the full cohort.
Why subjective and objective sleep findings differed
This pattern likely reflects the selected population. Participants entered with subjective sleep dissatisfaction but relatively healthy baseline objective sleep metrics — sleep efficiency averaged 86%, and average total sleep time was nearly seven hours [1]. That left limited room for major objective changes to surface.
What did the sleep subset analysis show?
In an exploratory subset of participants with more severe baseline sleep-related problems, the study reported a significant between-group difference in sleep disturbance and a larger difference in sleep-related impairment. Because these were subset analyses, they are best viewed as signals for future trials rather than definitive subgroup claims.
In plain terms: Participants reported less sleep-related daytime impairment, but the Oura Ring did not show between-group improvements in sleep duration, efficiency, or sleep stages. Subjective and objective outcomes therefore tell different parts of the story.
What did the trial report on heart rate and HRV?
The trial reported significant time-by-group differences for sleep-time heart rate (p = 0.030) and RMSSD heart rate variability (p = 0.036). Importantly, the increase in RMSSD within the Magtein® group alone was not statistically significant; the reported p = 0.036 refers to the difference in change between groups.
Importantly, these measures matter because autonomic balance influences how well the body transitions into recovery mode during sleep — a process closely linked to stress resilience, next-day energy, and cognitive performance.
RMSSD is commonly used as an indicator associated with parasympathetic nervous system activity. Taken together, lower sleep heart rate and higher HRV are broadly consistent with a body state that supports recovery [16].
Why this matters: HRV is a useful, indirect marker of autonomic regulation [17]. These findings are exploratory and do not establish improved cardiovascular health, stress resilience, or clinical outcomes, but they provide a testable direction for future Magtein® research.
Therefore, these findings open a new physiological dimension for future Magtein® research.
What did the trial report on tolerability?
Overall, participants tolerated Magtein® well. Treatment-related adverse-event rates were similar between groups, 98% of Magtein® participants rated tolerability as good or excellent, and no participant discontinued due to a treatment-related adverse event.
How should the findings be interpreted?
This six-week study provides encouraging evidence in 100 healthy adults aged 18–45 with self-reported dissatisfied sleep. The strongest findings involved overall cognition, working memory, sleep-related impairment, reaction time, sleep heart rate, and between-group HRV change. Future studies can build on these results through longer follow-up, broader age groups, and additional objective sleep measures. Readers can review the complete methodology and study details in the linked open-access paper.
Why does the 2026 Magtein clinical trial matter?
Beyond the individual findings, the 2026 Lopresti and Smith trial marks an important step in nutritional research on cognitive health.
Specifically, the trial shows:
rigorous study methods
thoughtful cohort design
broad outcome selection
expectancy-bias controls
objective wearable integration
and a clinical brain-health perspective
Overall, the findings are broadly consistent with previous Magtein® human studies conducted across different populations [6], [7], [8].
What the findings mean in practice
Researchers can use the study as a strong design template.
For formulators, the findings reinforce the growing clinical evidence base supporting the 2 g/day Magtein® protocol.
For clinicians and researchers, the exploratory subgroup findings support testing adults with greater baseline sleep-related difficulties in future trials; they do not yet identify a proven responder group.
Most importantly, the study reflects the continued growth of the Magtein® research platform. As a result, Magtein® remains one of the more clinically studied magnesium forms in cognition and sleep-health research, with a growing body of human and preclinical evidence behind it.
Independent replication, longer trials, and broader populations are still needed. Even so, the 2026 Magtein clinical trial adds human evidence on cognition, self-reported sleep-related impairment, and sleep-time autonomic measures—and gives future studies a clearer foundation to build on.
Related Magtein® research
FAQs
About magnesium L-threonate and the study
What is magnesium L-threonate?
In simple terms, magnesium L-threonate is a magnesium compound bound to L-threonic acid (a metabolite of vitamin C). For this reason, it was developed to address the limited evidence that most magnesium forms can meaningfully raise magnesium concentrations inside the brain after oral intake. In practice, Magtein® is the proprietary form of magnesium L-threonate used in published clinical trials on cognition and sleep.
What was the design of the 2026 Magtein clinical trial?
The 2026 Magtein clinical trial by Lopresti and Smith was a 6-week, two-arm, parallel-group, randomized, double-blind, placebo-controlled trial conducted in Australia [1]. Specifically, one hundred healthy adults aged 18 to 45 with self-reported dissatisfied sleep were randomly assigned to receive either 2 g daily of Magtein® or a placebo [1]. In addition, the investigators registered the trial on ANZCTR before it began, and the National Institute of Integrative Medicine Human Research Ethics Committee approved it.
What dose of Magtein® was used?
Participants received 2 g/day of Magtein®, split as 1 g in the morning and 1 g about two hours before bedtime. Together, the two daily doses delivered around 145 mg of elemental magnesium.
Results, timing, and tolerability
How long does Magtein® take to work?
The 2026 Lopresti and Smith trial assessed its main cognitive endpoint after six weeks. An earlier randomized sleep study assessed outcomes over three weeks. These study schedules do not establish exactly when an individual will notice an effect, and responses may vary. Follow the directions on the finished product and discuss supplement use with a qualified healthcare professional when appropriate.
What was the primary cognitive endpoint?
For cognition, the primary endpoint was the NIH Toolbox Total Cognition Composite, a validated computerized battery that evaluates working memory, attention, episodic memory, language, processing speed, and executive function.
What cognitive findings were reported?
Results showed a significantly greater improvement in the NIH Total Cognition Composite in the Magtein® group versus placebo (p = 0.043). In particular, the strongest signals appeared in working-memory-related outcomes.
Sleep, HRV, and tolerability
Did the study report sleep benefits?
Yes. In the trial, participants receiving Magtein® showed greater improvement in PROMIS Sleep-Related Impairment scores versus placebo. Moreover, participants with higher baseline sleep dissatisfaction showed larger effects.
Did the study report changes in heart rate variability (HRV)?
Yes. Specifically, the trial reported significant between-group differences in sleep heart rate and heart rate variability (HRV). Therefore, these exploratory findings open a new area for future Magtein® research.
Was Magtein® well tolerated?
Yes. Overall, adverse-event rates were similar between the placebo and Magtein® groups, and 98% of Magtein® participants rated tolerability as good or excellent.
Evidence and comparisons
Does this study apply to other magnesium forms?
No. Importantly, the study specifically investigated Magtein® and did not include head-to-head comparisons with other magnesium forms.
Do other oral magnesium forms have the same level of brain-related clinical evidence?
Currently, most other oral magnesium forms have limited published clinical evidence for brain-related outcomes such as cognition, sleep quality, or brain magnesium elevation. Therefore, the results should be interpreted as specific to Magtein® and should not be assumed to apply to other magnesium forms without direct clinical evidence.
Is magnesium glycinate supported by the same level of brain-related clinical evidence?
No head-to-head trial in this article compared Magtein® with magnesium glycinate. Evidence from a Magtein® trial should not be automatically transferred to a different magnesium form, and regulatory conclusions are ingredient- and use-specific. For a fuller comparison of the evidence, see Magtein® vs. Magnesium Glycinate.
Regulatory status
Is Magtein® FDA approved?
No. Dietary supplements are not FDA-approved in the way prescription drugs are. For GRAS Notice GRN 499, concerning magnesium L-threonate hydrate as a source of dietary magnesium in specified food uses, the FDA issued a “no questions” response in 2014 [18]. This is not product approval or a finding of clinical effectiveness. Separately, magnesium L-threonate received EU novel-food authorization in 2024 [19], and the UK register lists the Magtein® application as authorized [20]. Each authorization has its own scope and conditions of use.
Cognitive-age interpretation and the full paper
What was the 7.5-year cognitive age finding?
Specifically, the trial reported a 2.24-point group difference at week 6 on the NIH Toolbox Total Cognition Change Sensitive Score (p = 0.043). When applied to the NIH normative decline of about 0.3 points per year from age 20, this translates to a group difference of roughly 7.5 years on the normative curve. However, this derived metric expresses a between-group difference in age-equivalent terms; it does not directly measure biological cognitive age.
Where can I read the full paper?
For direct access, Frontiers in Nutrition published the study open-access: Lopresti AL, Smith SJ. The effects of magnesium L-threonate (Magtein®) on cognitive performance and sleep quality in adults: a randomised, double-blind, placebo-controlled trial. Front Nutr. (2026) 12:1729164. doi: 10.3389/fnut.2025.1729164
References
Clinical and mechanistic studies
[1]Lopresti AL, Smith SJ. The effects of magnesium L-threonate (Magtein®) on cognitive performance and sleep quality in adults: a randomised, double-blind, placebo-controlled trial. Front Nutr. (2026) 12:1729164. doi: 10.3389/fnut.2025.1729164
[2]Tao MH, Liu J, Cervantes D. Association between magnesium intake and cognition in US older adults: National Health and Nutrition Examination Survey (NHANES) 2011 to 2014. Alzheimers Dement (N Y). (2022) 8:e12250. doi: 10.1002/trc2.12250
[3]Passarelli S, Free CM, Shepon A, Beal T, Batis C, Golden CD. Global estimation of dietary micronutrient inadequacies: a modelling analysis. Lancet Glob Health. (2024) 12:e1590–e1599. doi: 10.1016/S2214-109X(24)00276-6
[4]Slutsky I, Abumaria N, Wu LJ, Huang C, Zhang L, Li B, et al. Enhancement of learning and memory by elevating brain magnesium. Neuron. (2010) 65:165–177. doi: 10.1016/j.neuron.2009.12.026
[5]Sun Q, Weinger JG, Mao F, Liu G. Regulation of structural and functional synapse density by L-threonate through modulation of intraneuronal magnesium concentration. Neuropharmacology. (2016) 108:426–439. doi: 10.1016/j.neuropharm.2016.05.006
Earlier human studies
[6]Liu G, Weinger JG, Lu ZL, Xue F, Sadeghpour S. Efficacy and safety of MMFS-01, a synapse density enhancer, for treating cognitive impairment in older adults: a randomized, double-blind, placebo-controlled trial. J Alzheimers Dis. (2016) 49:971–990. doi: 10.3233/JAD-150538
[7]Zhang C, Hu Q, Li S, Dai F, Qian W, Hewlings S, et al. A Magtein®, magnesium L-threonate-based formula improves brain cognitive functions in healthy Chinese adults. Nutrients. (2022) 14:5235. doi: 10.3390/nu14245235
[8]Hausenblas HA, Lynch T, Hooper S, Shrestha A, Rosendale D, Gu J. Magnesium-L-threonate improves sleep quality and daytime functioning in adults with self-reported sleep problems: a randomized controlled trial. Sleep Medicine X. (2024) 8:100121. doi: 10.1016/j.sleepx.2024.100121
Assessment tools and physiological measures
[9]Weintraub S, Dikmen SS, Heaton RK, Tulsky DS, Zelazo PD, Bauer PJ, et al. Cognition assessment using the NIH Toolbox. Neurology. (2013) 80:S54–S64. doi: 10.1212/WNL.0b013e3182872ded
[10]Raven J, Rust J, Chan F, Zhou X. Raven’s 2 Progressive Matrices, Clinical Edition (Raven’s 2). San Antonio, TX: Pearson (2018).
[11]Buysse DJ, Yu L, Moul DE, Germain A, Stover A, Dodds NE, et al. Development and validation of patient-reported outcome measures for sleep disturbance and sleep-related impairments. Sleep. (2010) 33:781–792. doi: 10.1093/sleep/33.6.781
[12]Drake CL, Hays RD, Morlock R, Wang F, Shikiar R, Frank L, et al. Development and evaluation of a measure to assess restorative sleep. J Clin Sleep Med. (2014) 10:733–741. doi: 10.5664/jcsm.3860
[13]Topp CW, Ostergaard SD, Sondergaard S, Bech P. The WHO-5 Well-being Index: a systematic review of the literature. Psychother Psychosom. (2015) 84:167–176. doi: 10.1159/000376585
Wearable, autonomic, and normative references
[14]Miller DJ, Sargent C, Roach GD. A validation of six wearable devices for estimating sleep, heart rate and heart rate variability in healthy adults. Sensors. (2022) 22:6317. doi: 10.3390/s22166317
[15]Laforte EM, Hook JN, Giella AK. National Institutes of Health (NIH) Toolbox® V3 Technical Manual. Illinois, USA: Northwestern University (2024).
[16]Hannon J, O’Hagan A, Lambe R, O’Grady B, Doherty C. Associations between daily heart rate variability and self-reported wellness: a 14-day observational study in healthy adults. Sensors (Basel). (2025) 25:4415. doi: 10.3390/s25144415
[17]Addleman JS, Lackey NS, DeBlauw JA, Hajduczok AG. Heart rate variability applications in strength and conditioning: a narrative review. J Funct Morphol Kinesiol. (2024) 9(2):93. doi: 10.3390/jfmk9020093
Regulatory sources
[18]U.S. Food and Drug Administration. GRAS Notice No. 499: Magnesium L-threonate hydrate. Closed September 3, 2014. FDA GRAS Notice inventory.
[19]European Commission. Commission Implementing Regulation (EU) 2024/2694 authorising the placing on the market of magnesium L-threonate as a novel food. EUR-Lex.
[20]UK Food Standards Agency. RP-956: Application for approval of MAGTEIN® Magnesium L-Threonate as a novel food. Status: authorised. FSA regulated-products register.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.